← Back
Data updated: Mar 10, 2026
CADILA
CardiovascularNeurologyOphthalmology
CADILA is a generic drug manufacturer focused on Cardiovascular, Neurology, Ophthalmology. Key products include VORICONAZOLE.
2016
Since
11
Drugs
-
Trials
133
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-17
Labeling
METRONIDAZOLE 2026-02-13
ACYCLOVIR 2026-01-22
Labeling
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE 2026-01-21
ACETAZOLAMIDE 2026-01-12
Labeling
ACETAZOLAMIDE 2026-01-08
Labeling
ACETAZOLAMIDE 2026-01-08
Labeling
ACETAZOLAMIDE 2026-01-08
Labeling
TIZANIDINE HYDROCHLORIDE 2025-12-16
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 52%
4 drugs
Neurology 13%
1 drugs
Ophthalmology 13%
1 drugs
Infectious Disease 13%
1 drugs
Immunology 9%
0 drugs Phase 3: 1
Pipeline Strength Pro
Loading...
Competitors Pro
AbbVie big-pharma
Immunology, Neurology, Infectious Disease, Ophthalmology
Novartis big-pharma
Cardiovascular, Immunology, Ophthalmology
BAUSCH AND LOMB specialty
Ophthalmology, Cardiovascular, Infectious Disease, Immunology
Merck big-pharma
Infectious Disease, Cardiovascular, Immunology
Baxter specialty
Infectious Disease, Cardiovascular, Ophthalmology
Active (6)
Discontinued (5)
Company Info
- First Approval
- 2016-03-25
- Latest
- 2025-10-23
- Applications
- 11